Search

Displaying results 2681 - 2690 of 6951 in total
  1. Drug

    Luteinizing hormone

    go.drugbank.com/drugs/DB14741
    ApprovedInvestigational

    Mixtures: MENOGON 75 IU Powder and Solvent for solution for Injection
  2. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

    Categories: Drugs for Constipation, Serotonin Receptor Agonists
  3. Drug

    Gemeprost

    go.drugbank.com/drugs/DB08964
    ApprovedWithdrawn

    Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. … It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy [A19726].

  4. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol.

  5. Drug

    Estradiol valerate

    go.drugbank.com/drugs/DB13956
    ApprovedInvestigationalVet approved

    due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation … Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.

    Categories: Hormonal Contraceptives for Systemic Use
  6. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. … [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  8. Target

    P2X purinoceptor 7

    go.drugbank.com/bio_entities/BE0009814
    TargetHumans

    ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small ca...

    Synonyms: ATP receptor, P2Z receptor
  9. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.

  10. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]